! Recent News !

Macrophage biology. Revealed

At Macomics we are applying our world-leading understanding of macrophage biology to the development of novel therapeutics that directly modulate macrophage activity in diseases where current therapeutics are severely limited or in many cases, ineffective.

We are passionate about the therapeutic potential of targeting macrophages. Our focus is on diseases where human genetic and clinical evidence points to a central role for macrophages in disease aetiology, including specific tumour subtypes, neurological conditions, fibrotic and inflammatory diseases. Our vision is to develop new approaches to targeting macrophage activity and thereby change the course of disease. We do this by exploiting genetically-evidenced disease-specific macrophage biology to effectively harness the power of macrophage direct effector functions.

Learn more

To meet this challenge, we have developed a proprietary Macomics discovery platform, called ENIGMAC™, proven through our pioneering work in cancer and now also leveraged in new disease areas. For the first time, ENIGMAC™ enables the translation of human disease specific macrophage biology into genetically validated and actionable therapeutic targets. We have brought together world-leading immunologists, drug discoverers, bioinformaticians and biologists. Founded by pre-eminent scientists in the field of macrophage immunology, our unparalleled expertise guides our mission to discover new therapies that improve the long-term outcome for patients.

Meet the team

We have a diversified portfolio of antibody and small molecule programs progressing towards the clinic and continue to identify new therapeutic targets through our proprietary ENIGMAC™ platform. By combining analysis of human disease tissue, in silico data mining, and functional data from our state-of-the-art cellular models we identify and validate new drug targets in diseases where macrophages play a central role.

Learn more

Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. Epidarex focuses on providing risk capital and expertise to create, support, and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs.

Scottish Enterprise is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. To deliver a significant, lasting effect on the Scottish economy, we work with partners in the public and private sectors to find and exploit the best opportunities.

The University of Edinburgh is one of the world’s top universities. Our partnership with the University of Edinburgh has allowed access to intellectual property that has enabled the development and progression of our portfolio.

LifeLink Ventures are an investment fund closing the gap between private capital and exciting new investment opportunities that tackle global health challenges. The LifeLink Ventures team is based in Barcelona, Spain, and they search for companies and work with investors across Europe and beyond. LifeLink Ventures deploy capital in alignment with a powerful cause – improvement in global health.

Dr Stephen Myatt

Chief Executive Officer

Dr Carola Ries

Chief Scientific Officer

Simon Dew

Chief Business Officer

Prof. Jeffrey W. Pollard

Founder – In Memoriam

Dr Luca Cassetta

VP Immunology and Founder

Richard Brooks

Consultant Head of Finance

Advisory panel

Dr John Haurum, M.D., D.Phil

Advisor

Prof. Michele De Palma

Advisor

Professor de Visser

Advisor

Dr Gomez-Roca

Advisor

Professor Speiser

Advisor

Professor Okkenhaug

Advisor

Dr Squadrito

Advisor

Dr Doody

Advisor

Dr Valérie Méresse Naegelen

Advisor

Professor Paul Crocker FRSE

Advisor